PD-Rx Pharmaceuticals, Inc.

OTCPK:PDRX Stock Report

Market Cap: US$5.9m

PD-Rx Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

PD-Rx Pharmaceuticals's earnings have been declining at an average annual rate of -103.2%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 25.9% per year.

Key information

-103.2%

Earnings growth rate

-103.3%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate-25.9%
Return on equity-0.9%
Net Margin-0.5%
Last Earnings Update30 Jun 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How PD-Rx Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:PDRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2321070
30 Jun 2229370
30 Jun 2122260
30 Jun 2021060
30 Jun 1921080
30 Jun 1825180
30 Jun 1726170
30 Jun 1621170
30 Jun 1519170
30 Jun 1429270

Quality Earnings: PDRX is currently unprofitable.

Growing Profit Margin: PDRX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PDRX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PDRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PDRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.3%).


Return on Equity

High ROE: PDRX has a negative Return on Equity (-0.87%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies